Similar articles

• Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.

  Keane FK, Chen MH, Zhang D, Moran BJ, Braccioforte MH, D'Amico AV. Keane FK, et al. Cancer. 2015 Aug 15;121(16):2713-9. doi: 10.1002/cncr.29420. Epub 2015 Apr 29. Cancer. 2015. PMID: 25925789
• Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.

  Falchook AD, Basak R, Mohiuddin JJ, Chen RC. Falchook AD, et al. Cancer. 2016 Aug 1;122(15):2341-9. doi: 10.1002/cncr.30049. Epub 2016 May 18. Cancer. 2016. PMID: 27191936
• The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.

  Dong Y, Ruth KJ, Churilla TM, Viterbo R, Sobczak ML, Smaldone MC, Chen DY, Uzzo RG, Hallman MH, Horwitz EM. Dong Y, et al. Can J Urol. 2017 Feb;24(1):8656-8662. Can J Urol. 2017. PMID: 28263132
• The role of androgen deprivation therapy plus radiation therapy in patients with non-metastatic prostate cancer.

  Zhao S, Urdaneta AI, Anscher MS. Zhao S, et al. Expert Rev Anticancer Ther. 2016 Sep;16(9):929-42. doi: 10.1080/14737140.2016.1218279. Epub 2016 Aug 5. Expert Rev Anticancer Ther. 2016. PMID: 27464256 Review.
• Traditional androgen ablation approaches to advanced prostate cancer: new insights.

  Rove KO, Crawford ED. Rove KO, et al. Can J Urol. 2014 Apr;21(2 Supp 1):14-21. Can J Urol. 2014. PMID: 24775719 Review.